RFK Jr. as HHS head is perhaps President-elect Donald Trump’s most controversial Cabinet pick now that Matt Gaetz has ...
A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma ...
AstraZeneca Fends Off Adcomm’s Safety Concerns on Andexxa, Axes Mid-Stage Opioid Use Disorder Drug
The pharma is seeking full approval for its anticoagulation reversal drug Andexxa, which the FDA granted accelerated approval ...
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand ...
Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...
Makary is a pancreatic surgeon at Johns Hopkins who became known for battling medical mistakes and in recent years has been ...
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...
Massachusetts’ increased investment in the life sciences industry includes boosting its life sciences tax incentive program ...
Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...
The agreement will give Kuro enough capital to support the development and launch of its menin inhibitor ziftomenib.
While the full impact of the Supreme Court decision remains unknown, the new regulatory landscape could be a net positive for ...
In this episode of Denatured, BioSpace's Head of Insights Lori and guests from Teva Pharmaceuticals and TOWER Capital Group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback